Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. George on Rationale for Abi Race Prostate Cancer Study

September 14th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the rationale for the Abi Race study looking at men with metastatic castration-resistant prostate cancer.

Dr. Posadas on Unmet Needs in Prostate Cancer

September 13th 2018

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses unmet needs in prostate cancer.

Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an Option

September 11th 2018

Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.

NCI Expert Stresses Importance of Multimodal Imaging in Prostate Cancer

September 7th 2018

Peter L. Choyke, MD, FACP, discusses the clinical implications of emerging technologies for prostate cancer imaging.

Dr. Hussain on Interest in Using PARP Inhibitors in Prostate Cancer

September 6th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the interest in using PARP inhibitors in patients with prostate cancer.

Enzalutamide/Radium-223 Combo Shows Tolerability in mCRPC

September 5th 2018

Benjamin L. Maughan, MD, PharmD, discusses the tolerability of combining radium-223 dichloride and enzalutamide, as well as the next steps with this combination.

Dr. George on Results of the Abi Race Study for Prostate Cancer

August 27th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses results of the Abi Race study for patients with metastatic castration-resistant prostate cancer.

Experts Delve Into 4 Phenotypes of Advanced Prostate Cancer

August 20th 2018

A panel of experts during an OncLive PeerExchange® provided practical definitions for biochemical recurrent hormone-naïve nonmetastatic, metastatic hormone-naïve advancing, nonmetastatic castration-resistant, and metastatic castration-resistant prostate cancer.

Overall Survival Analysis Between African-American and Caucasian Men with mCRPC

August 17th 2018

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Dr. Choyke on Differences Between PET Scans in Prostate Cancer

August 14th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the differences between PET scans in prostate cancer.

Survival Disparity Analysis Yields Unexpected Findings in mCRPC

August 13th 2018

Susan Halabi, PhD, discusses the unexpected results of a survival disparity analysis of African-American and Caucasian patients with metastatic castration-resistant prostate cancer.

Dr. Hussain on Potential of Enzalutamide in Prostate Cancer

August 9th 2018

Maha H. Hussain, MD, FACP, Genevieve Teuton Professor of Medicine, deputy director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the potential of enzalutamide in prostate cancer.

Expert Emphasizes Inclusivity in Prostate Cancer Trials

August 8th 2018

Daniel J. George, MD, discusses the findings from Abi Race and the implications they have on clinical trials in prostate cancer moving forward.

Dr. Samuelson on the Comorbidities that Affect Treatment Decisions in Prostate Cancer

August 8th 2018

Scott Samuelson, MD, medical oncologist at Utah Cancer Specialists, discusses the comorbidities that may affect treatment decisions for patients with metastatic prostate cancer.

Rethinking the Prostate Cancer Paradigm in the Urology Community

August 4th 2018

Raoul S. Concepcion, MD, FACS, discusses how to sort through the massive amount of data in the urology space, gain a basic understanding of its significance, and determine its clinical utility.

Dr. Yu on the Future of Castration-Sensitive Prostate Cancer

August 2nd 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the future of castration-sensitive prostate cancer.

ASCO Adds New Combos for Metastatic Noncastrate Prostate Cancer

July 31st 2018

Use of androgen deprivation therapy in combination with docetaxel or abiraterone in newly diagnosed cases of metastatic noncastrate prostate cancer is recommended in recently updated ASCO guidelines.

Practice in South Texas Offers Vertically Integrated Cancer Care

July 30th 2018

Providing comprehensive, compassionate, cost-effective care has been the guiding principle of Urology San Antonio. The practice manages over 200,000 visits and establishes relationships with more than 22,000 new patients each year.

Regulatory Decisions Propel Nonmetastatic CRPC Paradigm Forward

July 26th 2018

Mehmood Hashmi, MD, discusses the newly defined landscape of nonmetastatic castration-resistant prostate cancer, the potential with immunotherapy, and emerging imaging modalities.

Dr. Hussain on the Treatment of Nonmetastatic CRPC

July 25th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer.